NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis $2.67 0.00 (0.00%) Closing price 09/4/2026 04:00 PM EasternExtended Trading$2.69 +0.02 (+0.60%) As of 07:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About BioLineRx Stock (NASDAQ:BLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioLineRx alerts:Sign Up Key Stats Today's Range$2.55▼$2.7250-Day Range$2.60▼$3.2952-Week Range$2.15▼$4.56Volume27,888 shsAverage Volume26,064 shsMarket Capitalization$12.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management. Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors. In immunology and inflammatory diseases, the company is developing novel agents that modulate key biological pathways to reduce disease activity with minimal side effects. BioLineRx also explores treatments for neuropathic pain and other central nervous system conditions, seeking to offer new therapeutic options where few effective treatments exist. Headquartered in Modi’in, Israel, BioLineRx maintains strategic partnerships and licensing arrangements across North America, Europe and Asia to support its global development efforts. By leveraging a business model that combines in-licensing, co-development and out-licensing of assets, the company aims to maximize the value of its pipeline while managing development risk. BioLineRx collaborates with contract research organizations and clinical centers worldwide to conduct multi-site trials and accelerate the advancement of its drug candidates.AI Generated. May Contain Errors. Read More BioLineRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreBLRX MarketRank™: BioLineRx scored higher than 13% of companies evaluated by MarketBeat, and ranked 848th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBioLineRx has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioLineRx has only been the subject of 1 research reports in the past 90 days.Read more about BioLineRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($1.57) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioLineRx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.12% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 19.81, which indicates bearish sentiment.Change versus previous monthShort interest in BioLineRx has recently decreased by 0.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.10 News SentimentBioLineRx has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for BioLineRx this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by Insiders1.10% of the stock of BioLineRx is held by insiders.Percentage Held by Institutions1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLRX Stock News HeadlinesQ3 Earnings Forecast for BioLineRx Issued By HC WainwrightSeptember 4, 2026 | americanbankingnews.comBioLineRx Q2 Earnings Call HighlightsSeptember 3, 2026 | americanbankingnews.comCould the Feds Freeze Your Bank Account?The Department of Justice recently argued in court that cash isn't property - a claim that could reshape how much control you actually have over the money in your bank account. If your balance isn't legally guaranteed to be yours, who really controls it? Three strategies may help you prepare before any restrictions take hold.September 8 at 1:00 AM | Priority Gold (Ad)BLRX: New GLIX1 Data Touts SynergiesSeptember 1, 2026 | msn.comBioLineRx Ltd.: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 31, 2026 | finanznachrichten.deBioLineRx Ltd. (BLRX) Q2 2026 Earnings Call TranscriptAugust 31, 2026 | seekingalpha.comBioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 31, 2026 | prnewswire.comBioLineRx宣布375万美元股票发行计划，股价盘前下跌August 29, 2026 | cn.investing.comSee More Headlines BLRX Stock Analysis - Frequently Asked Questions How have BLRX shares performed this year? BioLineRx's stock was trading at $2.77 at the beginning of the year. Since then, BLRX shares have decreased by 3.6% and is now trading at $2.67. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings data on Monday, August, 31st. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.62. The biotechnology company earned $0.29 million during the quarter, compared to analysts' expectations of $0.50 million. BioLineRx had a negative net margin of 502.08% and a negative trailing twelve-month return on equity of 34.80%. Read the conference call transcript. When did BioLineRx's stock split? Shares of BioLineRx reverse split on Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA). Company Calendar Last Earnings8/31/2026Today9/08/2026Next Earnings (Estimated)11/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BLRX's financial health is in the Yellow zone, according to TradeSmith. BLRX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BLRX CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.17 million Net Margins-502.08% Pretax Margin-728.45% Return on Equity-34.80% Return on Assets-18.27% Debt Debt-to-Equity Ratio0.13 Current Ratio1.20 Quick Ratio1.04 Sales & Book Value Annual Sales$1.18 million Price / Sales10.97 Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book0.50Miscellaneous Outstanding Shares4,850,000Free Float4,796,000Market Cap$12.95 million OptionableOptionable Beta1.56 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BLRX) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersForget SpaceX, Elon Is Now Powering the Next Hot IPOElon Musk is backing a new AI startup that's quietly growing faster than Tesla, SpaceX, and reportedly 23 time...Brownstone Research | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredBuffett’s “Green New Deal” (trigger warning!)Warren Buffett's largest stock bet ever now tops 29 billion dollars, dwarfing his historic positions in Coca-C...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
